InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (1 ops.)
Browse the complete record of transactions filed by Olivier GIRE, Management Board Member. Director active across 1 companies, notably CROSSJECT. In total, 5 reports have been logged. Total volume traded: €29k. The latest transaction was filed on 24 June 2024 — Acquisition d'actions gratuites. Regulator: AMF. The full history is openly available.
Declarations5 total
020,000 shares0
ActionEuronext Paris
2024DD982993·
Ideal exit: 21 Mar 2025 (T+270)
07,500 shares0
ActionHors plateforme de négociation
2022DD867719·
Ideal exit: 14 Jul 2023 (T+270)
€3,4451,276 shares@ €2.700.0030% mcap12.0% of flow
ActionHors plateforme de négociation
2022DD867720·
Ideal exit: 15 Jul 2023 (T+270)
€1827,811 shares@ €0.02330.0002% mcap0.6% of flow
Bon de Souscription d'ActionEuronext Growth Paris
2022DD848287·
€25,00214,100 shares@ €1.77320.022% mcap87.3% of flow
ActionEuronext Growth Paris
2022DD848289·
Ideal exit: 17 Mar 2023 (T+270)
5 of 5 declarations
About Olivier GIRE
Olivier Giré is a French executive in the specialty pharmaceutical industry, known for his expertise in international markets, commercial development, and the build-out of distribution networks in healthcare. At CROSSJECT, the French listed pharma company developing the needle-free ZENEO® auto-injector platform, he held a key leadership role as Chief COO Specialty Pharma and served as a member of the Executive Board from September 14, 2016. His board mandate was not renewed in February 2025 as part of a governance reshaping linked to the final regulatory steps for ZEPIZURE® with the U.S. FDA and the company’s preparation for direct commercialization in the United States. Before and during his tenure at CROSSJECT, Olivier Giré built a career spanning more than twenty years in the pharmaceutical industry, working with several international specialty laboratories. CROSSJECT states that he spent more than twelve years at IPSEN, and also worked for AMDIPHARM and EXELTIS. His track record includes creating and leading commercial subsidiaries with more than 200 employees, as well as managing international distributor networks of more than 50 partners across nearly 100 countries. This background highlights strong capabilities in international commercial structuring, innovative product launches, and the management of multi-specialty therapeutic portfolios. At CROSSJECT, Olivier Giré played an important role in strengthening relationships with international partners and in the operational validation of the ZENEO® platform. In 2025, the company publicly thanked him for his major contribution to the quality of those partnerships and to the operational milestones that helped validate the technology. CROSSJECT also highlighted his involvement in strategic developments around ZEPIZURE® and the company’s other pipeline candidates, as well as in scaling the business for future growth in target markets. A graduate of EDHEC Business School, Olivier Giré combines a strong academic background with hands-on executive experience at the intersection of commercial strategy, operational execution, and growth delivery.
